linjc16/ctgov huggingface dataset:
EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

Study Overview
=================
Brief Summary
-----------------
Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world. In Egypt, breast cancer represents the 2nd most diagnosed cancer among all population. But among Egyptian females it represents the 1st diagnosed cancer representing 32.4%. The main cause of death in breast cancer patients is tumor metastasis. Although only 5-10% of recently diagnosed breast cancer cases show metastasis to distant sites, but still there is a high risk for metastasis in patients with localized primary tumor following successful surgical management. Epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule. It modifies cadherin mediated cell adhesion and it induces epithelial cell migration and proliferation. Some authors elucidate that EpCAM is involved in metastasis. P53 is a known tumor suppressor gene involved in the control of cell cycle, DNA repair and apoptosis. It's one of the most mutated genes in cancer including breast cancer. Mutant p53 has a big role in tumor progression.

Official Title
-----------------
EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast and Their Association With the Clinicopathological Prognostic Paremeters

Conditions
-----------------
Invasive Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Both incisional and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study. 3. Complete clinical data. Exclusion Criteria: Patients with recurrence of the primary tumor. Patients with a history of preoperative chemotherapy and/or radiotherapy. Insufficient or tiny tissue biopsies

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of breast cancer | Immunohistochemical expression of EpCAM and P53 in IDC of the breast | two day after staining sections with Immnnohistochemical markers | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EpCAM, P53 , IDC
Cardiovascular and Cerebrovascular Control in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate autonomic function and cerebrovascular control in 30 healthy subjects by means of noninvasive analysis of time series variability. To this extent, heart period, systolic and mean arterial blood pressure, cerebral blood velocity, peripheral resistances, respiration will be recorded from subjects during an orthostatic challenge. The interactions between autonomic cardiovascular function, cerebrovascular and peripheral control will be evaluated exploiting the most advanced signal processing techniques.

Official Title
-----------------
Cardiovascular and Cerebrovascular Control in Healthy Adult Subjects

Conditions
-----------------
Healthy, Autonomic Nervous System, Cerebral Autoregulation

Intervention / Treatment
-----------------
* Diagnostic Test: active standing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >18 sinus rhythm informed consent signed Exclusion Criteria: age <18 presence of autonomic nervous system diseases or dysfunctions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy<br>30 healthy subjects; age >18; sinus rhythm; absence of autonomic diseases or dysfunctions. | Diagnostic Test: active standing<br>* Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the state and interactions of autonomic function and cerebrovascular control |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
autonomic nervous system, heart rate variability, cerebral autoregulation, peripheral resistances
Physiological Effects Ketone Ester in Heart

Study Overview
=================
Brief Summary
-----------------
The study is aimed to phenotype with cardiac MRI the physiological effects of ketone esters on the heart. Patients with heart failure will be recruited and given ketone esters or placebo in a randomized fashion. Cardiac MRI will be performed at baseline and after 12weeks follow up.

Official Title
-----------------
Physiological Effects of Dietary Supplement Ketone Ester on the Heart

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Dietary Supplement: Ketone Ester
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: heart failure EF < 40% Exclusion Criteria: Claustrophobia Contraindicated implanted device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Placebo vs intervention group. Ketone ester is NOT a drug and only used to see the physiological effects on the heart.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Placebo given that mimics taste, weight, and size of the interventional supplement mirroring the same time points as the ketone ester supplement group. Mirrored imaging with MRI as well. | Dietary Supplement: Placebo<br>* Added to water or lemonade 3 times per day.<br>|
| Experimental: Ketone ester supplement<br>Ketone ester given daily for 12 weeks and scanned before and after intervention with MRI. | Dietary Supplement: Ketone Ester<br>* Added to water or lemonade 3 times per day.<br>* Other names: delta G;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Left Ventricular Ejection Fraction | Measured with cardiac MRI the left ventricular ejection fraction at two points and then delta is calculated | Pre-intervention and up to 12 weeks after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Creatine concentration | Measured with cardiac MRI the creatine concentration at two points and then delta is calculated | Pre-intervention and up to 12 weeks after intervention |
Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.

Official Title
-----------------
Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease

Conditions
-----------------
Chronic Kidney Diseases, Acute Heart Failure, Biomarker

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hospitalized for acute heart failure Exclusion Criteria: initial serum NT-proBNP level <300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major adverse cardiovascular events | mortality, acute myocardial infarction, acute stroke, and heart failure hospitalization | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major adverse kidney events | mortality, new end-stage renal disease, and 30% decline in estimated GFR | 1 year |
Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates

Study Overview
=================
Brief Summary
-----------------
This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.

Official Title
-----------------
Upstaging and Lymph Node Metastasis Rate in Patients With Ductal Carcinoma in Situ Who Received Mastectomy Regarding the Necessary of Sentinel Lymph Node Biopsy

Conditions
-----------------
Ductal Carcinoma in Situ

Intervention / Treatment
-----------------
* Procedure: Mastectomy with sentinel lymph node biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women diagnosed with DCIS in preoperative biopsy samples obtained by core needle biopsy, vacuum-assisted breast biopsy, or excisional biopsy Women underwent curative surgery for DCIS Exclusion Criteria: Patients who received breast-conserving surgery Patients who had concurrent contralateral invasive breast cancer Patients who were in case of ipsilateral breast tumor recurrence Patients whose invasiveness was uncertain in the biopsy samples

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DCIS Mastectomy<br>Patients who undergo mastectomy with sentinel lymph node biopsy for DCIS at biopsy | Procedure: Mastectomy with sentinel lymph node biopsy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Axillary lymph node metastasis rate | Our primary objective was to identify the axillary lymph node metastasis rate in patients with DCIS at diagnosis who underwent mastectomy with axillary surgery. | up to 2 weeks after surgery |
Ate-Bev Early Response Prediction Model in Advanced HCC

Study Overview
=================
Brief Summary
-----------------
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.

Official Title
-----------------
Developing Atezolizumab-Bevacizumab Treatment Response Early Prediction Model in Advanced Hepatocellular Carcinoma Patients

Conditions
-----------------
Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation

Intervention / Treatment
-----------------
* Diagnostic Test: Early response evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy Patients willing to participate in this study Exclusion Criteria: Individuals with a history of severe contrast allergy Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ate-Bev<br>Individuals diagnosed with advanced hepatocellular carcinoma and treated with atezolizumab-bevacizumab between the ages of 18-80 were included. According to the recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, patients with comorbidities were excluded. | Diagnostic Test: Early response evaluation<br>* Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival | the index date is the date of treatment with atezolizumab and bevacizumab, and the event is either death or tumor progression of the tumor. | the follow up will be continued until June 22th 2025. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | the index date is the date of treatment with atezolizumab and bevacizumab, and the event is death. | the follow up will be continued until June 22th 2025. |
Computed Tomography Scanning in ICU

Study Overview
=================
Brief Summary
-----------------
Patients admitted to the intensive care unit often require CT imaging. Performing this diagnostic test on a critically ill patient involves risks, such as those associated with transferring a ventilated and unstable patient and those associated with the injection of intravenous contrast material. Also, multiple CT examinations may create a burden on the X-ray institute and the medical staff, result in the postponement of CT examinations for other patients, as well as increase hospitalization costs. In this work, we would like to check the rate of complications involved in performing a CT scan in patients hospitalized in the general intensive care unit of our institution, while analyzing the differences between the times the test is performed (morning, night shift), as well as examine in what percentage of the CT scans the test performed contributed to a significant progress in the diagnosis or a significant change in the treatment plan of the patient, while referring to subgroups (sepsis, trauma, respiratory failure, with an emphasis on covid patients, patients with scoliosis, patients with intracranial pathology).

Official Title
-----------------
Impact of Computed Tomography Scanning on ICU Patient Management: Retrospective Study

Conditions
-----------------
CT Scans in the Intensive Care Unit

Intervention / Treatment
-----------------
* Diagnostic Test: CT scan in critically ill patients in the intensive care unit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:All patients who underwent CT examinations during hospitalization in the intensive care unit for any etiology, from January 2020 to January 2023. - Exclusion Criteria:Patients who did not meet the above criteria or for whom data were missing. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CT scan in critically ill patients in the intensive care unit|CT scan in critically ill patients in the intensive care unit|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in diagnosis and/or patient management | To examine in what percentage of the CT examinations the examination contributed to a significant progress in the diagnosis or a significant change in the patient's treatment plan, while referring to subgroups of patients in the intensive care unit. | 3 years |
Chronic Prostatitis/Chronic Pelvic Pain Syndrome Patients

Study Overview
=================
Brief Summary
-----------------
Chronic prostatitis/chronic pelvic pain syndrome (CPPS) is a common health problem among men and can cause severe quality of life. The pathophysiology of CPPS is still poorly understood and effective treatments are a challenging issue. This study aims to investigate the possible relationship between the presence of microorganisms in the prostatic fluid and symptom severity by presenting a retrospective analysis based on data from CPPS patients.

Detailed Description
-----------------
This study is based on data from 112 CPPS patients aged 20-60 years. Various variables such as demographic information of the patients, International Prostate Symptom Score (I-PSS), which evaluates CPPS symptoms, inflammatory and non-inflammatory symptoms of CPPS, baseline scores of the International Index of Erectile Function (IIEF), which evaluates erectile function, and the presence of microorganisms in the prostate fluid were analyzed retrospectively.

Official Title
-----------------
Retrospective Data Analysis in Chronic Prostatitis/Chronic Pelvic Pain Syndrome Patients: Evaluation of the Relationship Between Presence of Microorganism and Severity of Symptom

Conditions
-----------------
Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: Chronic prostatitis/chronic pelvic pain syndrome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were diagnosed with chronic prostatitis/chronic pelvic pain syndrome and whose prostate fluid was taken with prostate massage and androflor testis were studied were included. Exclusion Criteria: acute and/or chronic bacterial prostatitis, active history of genitourinary cancer, history of recent prostate surgery the diagnosis of neurological diseases affecting the bladder was determined

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| singel<br> | Diagnostic Test: Chronic prostatitis/chronic pelvic pain syndrome<br>* Chronic prostatitis/chronic pelvic pain syndrome UPOINT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between androflor pcr positive patients and uopint and nih-cpsi | Those with positive and negative Androflor PCR test will be evaluated. testicular torsion | 2 years |
Training and Evaluation of Ultrasound-Guided Procedures

Study Overview
=================
Brief Summary
-----------------
38 certified registered nurse anesthetist (CRNA) students will learn 5 different ultrasound-guided regional anesthesia blocks both with and without a novel device, the EDU which gives the student help finding the right needle path.

Detailed Description
-----------------
38 students enrolled in a course for ultrasound-guided nerve blocks will be participants in a study to evaluate the benefit of learning with ultrasound guidance. The EDU, a computer assisted guide for ultrasound interventions will be used for half the students for each of 5 nerve blocks/interventional procedures. Then the students will switch (crossover study) and perform the same interventions. Data will be recorded by dint of the tiny video cameras on the EDU and anonymized and evaluated.

Official Title
-----------------
Training and Evaluation of Ultrasound-Guided Procedures

Conditions
-----------------
Learning Anesthesia Procedures

Intervention / Treatment
-----------------
* Device: With EDU


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All CRNA students in Dr. Hauglum's class on ultrasound-guided nerve blocks - Exclusion Criteria: Any CRNA students who drop Dr. Hauglum's class on ultrasound-guided nerve blocks -

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: learning with the EDU<br>Students will perform 5 ultrasound-guided regional anesthesia procedures on a phantom using the EDU which shows the student how to hold the needle and probe to hit the target. | Device: With EDU<br>* using the EDU to perform the procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance to target | how close did the student come to the instructor-specified target | Day 1 | 
| number of redirects | how many times did the student withdraw the needle and start again | Day 1 |